Navigation Links
Naviscan Further Strengthens its Board of Directors With the Addition of Dr. Andre Cheng
Date:7/14/2011

SAN DIEGO, July 14, 2011 /PRNewswire/ -- Naviscan, Inc., the worldwide leader in 3D Molecular Breast Imaging (MBI), announced today that Andre Cheng MD, PhD has joined the Naviscan Board of Directors.

Dr. Cheng has extensive clinical and business experience related to reimbursement in the medical device industry.  He served as the Vice President of Medical Affairs and Reimbursement at Acclarent, Inc.  After acquisition by Ethicon, Inc., a Johnson & Johnson company, he served as Worldwide Vice President of Health Economics and Reimbursement at Ethicon.  Prior to this he was a Managing Partner at The Advisory Board Company.  Dr. Cheng is a graduate of the Johns Hopkins School of Medicine and holds a PhD in Clinical Investigation and Healthcare Economics from the Johns Hopkins School of Public Health.

"Dr. Cheng is an acknowledged physician and scientist with extensive, relevant expertise and a track record of extraordinary success in securing reimbursement for new technologies," stated Paul Mirabella, Chairman and CEO.  "As we expand our global reach and market penetration into new areas of the patient care cycle, adding Andre to our Board will further strengthen Naviscan's already solid reimbursement and clinical impact."

Naviscan manufactures the only commercially-available organ-specific, high resolution PET scanner, the breast applications for which are Positron Emission Mammography (PEM) and PEM-guided biopsy.  The scanner uses PET technology to produce tomographic images that allow physicians to visualize and biopsy breast tumors as small as 1.3 mm.  In recently published data, PEM has been found to be significantly more precise at identifying benign and cancerous lesions—what scientists call "specificity"—and therefore has the potential to reduce the number of unnecessary biopsies.  This finding is a welcomed outcome for women and physicians looking for ways to reduce the patient trauma and cost associated with unnecessary procedures.  

About Naviscan, Inc.

Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the U.S. and other parts of the world. The Company is headquartered in San Diego, California and is the first to obtain FDA-clearance for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, call 1.858.587.3641 or visit www.naviscan.com


'/>"/>
SOURCE Naviscan, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Coast Oncology Deploying Both Naviscan(TM) PEM and AccuBoost(TM) Assisted Therapy to Optimize Breast Cancer Treatment
2. Baylor Adds Naviscan PEM Technology to Womens Imaging Center
3. Johns Hopkins Medicine Acquires Naviscan PEM Technology for Novel Radiotracer Research
4. Naviscan Positron Emission Mammography Technology Highlighted at the Society of Nuclear Medicine Annual Meeting
5. SightLine Health Adds Naviscan PEM Technology to Breast Cancer Treatment Services
6. Naviscan® Announces Collaboration With Neoprobe Corporation to Enable Pipeline Technology Development
7. Naviscan Announces European Launch of Positron Emission Mammography
8. Naviscan Announces Partnership With Chindex Medical Limited for Mainland China, Hong Kong and Macau
9. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
10. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
11. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... February 24, 2017 Following receiving ... Israel , s AMAR is a major ... 250 M w ound care market in ... BST for inclusion in the National Health Basket ...   E-QURE Corp. (OTCQB: EQUR), a leader ...
(Date:2/24/2017)... Research and Markets has announced the addition of ... report to their offering. ... The latest research Dry eye Drugs Price Analysis and Strategies - 2016, ... The research answers the following questions: ... attributes? How are they positioned in the Global Dry eye market? ...
(Date:2/24/2017)... SILVER SPRING, Md. , Feb. 23, 2017 ... today allowed marketing of the PhenoTest BC Kit, ... first test to identify organisms that cause bloodstream ... organism is likely to respond to (antibiotic sensitivity). ... it takes to provide this important information, which ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... 2017 , ... The threat of nuclear warfare has long plagued this world. ... the underground testing of nuclear weapons. Years later, when her co-workers began dying, Dot ... War Nuclear Testing,” Clayton exposes the critical decisions made by agencies involved in the ...
(Date:2/27/2017)... ... February 27, 2017 , ... Orange County dentist, ... inflammatory gum condition that occurs when the bacteria in plaque infect the gums and ... as a scaling and root planing or SRP, and can include surgical therapies if ...
(Date:2/27/2017)... ... , ... Miro is the ultimate smart media center that offers a fascinating ... shows and much more apps for user exploration. Its innovative acoustic design with premium ... x 720 provides crisp images with remarkable clarity and color. The WiFi connection enables ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... customer threshold mark last week. In addition, Discount Power's RCE (Residential Customer Equivalent) ... LLC in March 2014. The company had 800 customers and 2,250 RCEs at ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair ... announce a new informational post on robotic hair transplantation. San Francisco residents may ... transplant and Follicular Unit Transplantation (FUT) can sound similar. Either treatment can be ...
Breaking Medicine News(10 mins):